KCI shareholders approve buyout; Everist completes Angiologix purchase;

> Kinetic Concepts ($KCI) shareholders have approved the acquisition of the company for $68.50 per common share in cash, or a total value of about $6.3 billion, including outstanding debt. The acquisition is expected to close in early November. KCI release

> Everist Genomics has completed the buy of 100% of the shares of Angiologix, the developer of the AngioDefender diagnostic device for assessing endothelial function. Everist release

> Minister for Jobs, Enterprise and Innovation Richard Bruton is on a 5-day mission in the U.S. to discuss proposals for investment and job creation in Ireland with senior execs from 19 companies. Seven companies he will meet with are in the life sciences sector. Story

> ARKRAY USA's Glucocard Vital and 01 are now listed on the Department of Defense Uniform Formulary. ARKRAY release

> Baxano is expanding its sales infrastructure to meet the rising demand for its products. "We are very optimistic about Baxano's current success and future prospects," said CEO Tony Recupero. "Our monthly sales have grown 300% during the first three quarters of 2011 and Q4 is showing even stronger growth rates." Baxano release

And Finally... A laser powerful enough to tear apart the fabric of space could be built in Britain. In addition to offering insights into undiscovered realms of physics, scientists say the lasers will also produce new treatments for cancer and medical diagnostics. Story

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.